Thermo Fisher Scientific acquires Finnzymes

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Finnzymes. The business is a well-recognized provider of integrated tools for high-performance polymerase chain reaction (PCR), including reagents, instruments, consumables and kits that make the PCR process faster and more accurate for applications including basic genomic research, genetic testing, forensics and food safety.

Finnzymes, which generated full year 2009 revenues of $20 million, will be integrated primarily into Thermo Fisher’s Analytical Technologies Segment, with certain equipment and consumables product lines being added to the Laboratory Products and Services Segment.

Source:

Thermo Fisher Scientific Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2019, June 20). Thermo Fisher Scientific acquires Finnzymes. News-Medical. Retrieved on July 29, 2021 from https://www.news-medical.net/news/20100305/Thermo-Fisher-Scientific-acquires-Finnzymes.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific acquires Finnzymes". News-Medical. 29 July 2021. <https://www.news-medical.net/news/20100305/Thermo-Fisher-Scientific-acquires-Finnzymes.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific acquires Finnzymes". News-Medical. https://www.news-medical.net/news/20100305/Thermo-Fisher-Scientific-acquires-Finnzymes.aspx. (accessed July 29, 2021).

  • Harvard

    Thermo Fisher Scientific Inc.. 2019. Thermo Fisher Scientific acquires Finnzymes. News-Medical, viewed 29 July 2021, https://www.news-medical.net/news/20100305/Thermo-Fisher-Scientific-acquires-Finnzymes.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Thermo Fisher Scientific continues to support the development of COVID-19 vaccines, therapies